Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study

J. Menczer; G. Ben-Baruch; S. Rizel; H. Brenner

Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study

J. Menczer^*, G. Ben-Baruch, S. Rizel, H. Brenner

^*Corresponding author for this work

Sheba Medical Center at Tel Hashomer

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Effective second line chemotherapy schedules for recurrent ovarian carcinoma are not available. The combination of cisplatin and VP-16 given as a single dose in such patients gave inconsistent results. Since VP-16 is a dose-schedule dependant drug it was given in this pilot study as a continuous 72 hour infusion at a dose of 100 mg/m²/day. No objective response was observed among 7 patients with refractory or recurrent ovarian carcinoma who received a median of 3 treatment courses.

Original language	English
Pages (from-to)	316-318
Number of pages	3
Journal	European Journal of Gynaecological Oncology
Volume	13
Issue number	4
State	Published - 1992
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{baef88239fc64782b55f789f002a0e27,

title = "Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study",

abstract = "Effective second line chemotherapy schedules for recurrent ovarian carcinoma are not available. The combination of cisplatin and VP-16 given as a single dose in such patients gave inconsistent results. Since VP-16 is a dose-schedule dependant drug it was given in this pilot study as a continuous 72 hour infusion at a dose of 100 mg/m2/day. No objective response was observed among 7 patients with refractory or recurrent ovarian carcinoma who received a median of 3 treatment courses.",

author = "J. Menczer and G. Ben-Baruch and S. Rizel and H. Brenner",

year = "1992",

language = "אנגלית",

volume = "13",

pages = "316--318",

journal = "European Journal of Gynaecological Oncology",

issn = "0392-2936",

publisher = "S.O.G. CANADA Inc.",

number = "4",

}

TY - JOUR

T1 - Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study

AU - Menczer, J.

AU - Ben-Baruch, G.

AU - Rizel, S.

AU - Brenner, H.

PY - 1992

Y1 - 1992

N2 - Effective second line chemotherapy schedules for recurrent ovarian carcinoma are not available. The combination of cisplatin and VP-16 given as a single dose in such patients gave inconsistent results. Since VP-16 is a dose-schedule dependant drug it was given in this pilot study as a continuous 72 hour infusion at a dose of 100 mg/m2/day. No objective response was observed among 7 patients with refractory or recurrent ovarian carcinoma who received a median of 3 treatment courses.

AB - Effective second line chemotherapy schedules for recurrent ovarian carcinoma are not available. The combination of cisplatin and VP-16 given as a single dose in such patients gave inconsistent results. Since VP-16 is a dose-schedule dependant drug it was given in this pilot study as a continuous 72 hour infusion at a dose of 100 mg/m2/day. No objective response was observed among 7 patients with refractory or recurrent ovarian carcinoma who received a median of 3 treatment courses.

UR - http://www.scopus.com/inward/record.url?scp=0026751306&partnerID=8YFLogxK

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:0026751306

SN - 0392-2936

VL - 13

SP - 316

EP - 318

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

IS - 4

ER -

Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this